A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer (Q36546241)

14 August 2017

A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer (English)

1 reference

14 August 2017

1 reference

C J Paller

1

1 reference

14 August 2017

X Ye

2

1 reference

14 August 2017

P J Wozniak

3

1 reference

14 August 2017

B K Gillespie

4

1 reference

14 August 2017

P R Sieber

5

1 reference

14 August 2017

R H Greengold

6

1 reference

14 August 2017

B R Stockton

7

1 reference

14 August 2017

B L Hertzman

8

1 reference

14 August 2017

M D Efros

9

1 reference

14 August 2017

R P Roper

10

1 reference

14 August 2017

H R Liker

11

1 reference

14 August 2017

M A Carducci

12

1 reference

14 August 2017

12 June 2012

1 reference

Prostate Cancer and Prostatic Diseases

14 August 2017

1 reference

14 August 2017

16

1 reference

14 August 2017

1

1 reference

14 August 2017

50-55

1 reference

https://scigraph.springernature.com/pub.10.1038/pcan.2012.20

14 August 2017

0 references

cites work

Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

The bioactivity of pomegranate: impact on health and disease.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Defining the Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Impact of biochemical recurrence in prostate cancer among US veterans

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Molecular targets of dietary agents for prevention and therapy of cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

The chemopreventive properties of soy isoflavonoids in animal models of breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Prostate cancer prevention through pomegranate fruit.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3549301

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

21 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FPCAN.2012.20

31 March 2020

Identifiers

DOI

10.1038/PCAN.2012.20

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

22689129

1 reference